-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RjO1Vea72v1l53iW/qYi93iLM6MhtvK9uu2z0pGR8eJ0CroF7gogBCOxLdqfOCdX yY5FWxhEeKSDqNy5Df40pQ== 0000914233-96-000038.txt : 19960517 0000914233-96-000038.hdr.sgml : 19960517 ACCESSION NUMBER: 0000914233-96-000038 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19960331 FILED AS OF DATE: 19960515 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: UTAH MEDICAL PRODUCTS INC CENTRAL INDEX KEY: 0000706698 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 870342734 STATE OF INCORPORATION: UT FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-11178 FILM NUMBER: 96564701 BUSINESS ADDRESS: STREET 1: 7043 S 300 WEST CITY: MIDVALE STATE: UT ZIP: 84047 BUSINESS PHONE: 8015661200 10-Q 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Quarterly Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For quarter ended: March 31, 1996 Commission File No. 0-11178 UTAH MEDICAL PRODUCTS, INC. (Exact name of Registrant as specified in its charter) UTAH 87-0342734 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 7043 South 300 West Midvale, Utah 84047 Address of principal executive offices Registrant's telephone number: (801) 566-1200 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and; (2) has been subject to such filing requirements for the past 90 days. Yes X No - The number of shares outstanding of the registrant's common stock as of May 13, 1996: 9,296,104 UTAH MEDICAL PRODUCTS, INC. --------------------------- INDEX TO FORM 10-Q ------------------ PART I - FINANCIAL INFORMATION PAGE ---- Item 1. Financial Statements Balance Sheets as of March 31, 1996 and December 31, 1995 1 Statements of Operations for the three months ended March 31, 1996 and March 31, 1995 2 Statements of Cash Flows for the three months ended March 31, 1996 and March 31, 1995 3 Notes to Financial Statements 4 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 5 PART II - OTHER INFORMATION Item 6. Exhibits and Reports on Form 8-K 8 SIGNATURES 8 PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARY ------------------------------------------ BALANCE SHEETS AS OF MARCH 31, 1996 AND --------------------------------------- DECEMBER 31, 1995 ----------------- (unaudited) ASSETS MARCH 31, 1996 DECEMBER 31,1995 -------------- ---------------- CURRENT ASSETS: Cash $8,398,387 $5,064,913 Investments 7,343,850 8,173,500 Accounts receivable - net 5,538,785 6,473,810 Accrued interest and other 177,902 221,662 Inventories 3,618,724 3,277,982 Prepaid expenses 296,296 244,675 Deferred income taxes 435,325 372,899 ------------- ------------ Total current assets 25,809,269 23,829,441 PROPERTY AND EQUIPMENT - NET 9,555,909 8,866,359 INTANGIBLE ASSETS - NET 586,119 634,579 ------------- ------------ TOTAL $ 35,951,297 $33,330,379 ============= ============ LIABILITIES AND STOCKHOLDERS' EQUITY - ------------------------------------ CURRENT LIABILITIES: Accounts payable $ 1,694,992 $ 1,783,840 Accrued expenses: Payroll and payroll taxes 1,002,296 1,197,692 Reserve for litigation expense 427,464 314,619 Income taxes payable 1,227,662 105,024 Other 240,590 220,750 Deferred revenue 85,600 85,600 ------------- ------------ Total current liabilities 4,678,604 3,707,525 DEFERRED REVENUE 151,779 173,208 DEFERRED INCOME TAXES 344,294 245,289 ------------- ------------ Total liabilities 5,174,677 4,126,022 ------------- ------------ STOCKHOLDERS' EQUITY: Preferred stock - $.01 par value; authorized - 5,000,000 shares; no shares issued or outstanding Common stock - $.01 par value; authorized - 50,000,000 shares; issued - March 31, 1996, 9,727,341 shares December 31, 1995, 9,790,937 shares 97,273 97,909 Unrealized gain on investments available-for-sale, net of tax 23,610 32,707 Retained earnings 30,655,737 29,073,741 ------------- ------------ Total stockholders' equity 30,776,620 29,204,357 ------------- ------------ TOTAL $35,951,297 $33,330,379 ============= ============ see notes to consolidated financial statements UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARY ------------------------------------------ STATEMENTS OF OPERATIONS FOR THE THREE MONTHS --------------------------------------------- ENDED MARCH 31, 1996 AND MARCH 31, 1995 --------------------------------------- (unaudited) THREE MONTHS ENDED MARCH 31, ----------------------------- 1996 1995 ------------- -------------- NET SALES $9,967,590 $9,754,041 COST OF SALES 5,372,531 5,382,678 ------------- -------------- GROSS MARGIN 4,595,059 4,371,363 ------------- -------------- EXPENSES: Selling, general and administrative 1,448,347 1,422,878 Research & development 358,874 417,337 ------------- -------------- Total 1,807,221 1,840,215 ------------- -------------- INCOME FROM OPERATIONS 2,787,838 2,531,148 OTHER INCOME 1,098,758 269,646 ------------- -------------- INCOME BEFORE INCOME TAX EXPENSE 3,886,596 2,800,794 INCOME TAX EXPENSE 1,403,061 980,277 ------------- -------------- NET INCOME $2,483,535 $1,820,517 ============= ============== EARNINGS PER COMMON AND COMMON EQUIVALENT SHARE $0.25 $0.18 ============= ============== EARNINGS PER COMMON SHARE ASSUMING FULL DILUTION $0.25 $0.18 ============= ============== WEIGHTED AVERAGE NUMBER OF COMMON AND COMMON EQUIVALENT SHARES 10,041,513 10,069,086 ============= ============== WEIGHTED AVERAGE NUMBER OF COMMON SHARES ASSUMING FULL DILUTION 10,041,513 10,069,086 ============= ============== see notes to consolidated financial statements UTAH MEDICAL PRODUCTS, INC. AND SUBSIDIARY ------------------------------------------ STATEMENTS OF CASH FLOWS ------------------------ FOR THE THREE MONTHS ENDED MARCH 31, 1996 AND MARCH 31, 1995 ------------------------------------------------------------ (unaudited) MARCH 31, -------------------------- 1996 1995 ------------ ------------ CASH FLOWS FROM OPERATING ACTIVITIES: Net income $2,483,535 $1,820,517 ------------ ------------ Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 341,807 408,678 Provision for losses on accounts 11,385 5,621 receivable Loss on disposal of assets 372,311 5,171 Deferred income taxes 42,114 74,013 Tax benefit attributable to exercise and disposition of incentive stock options and stock purchase rights 56,383 18,978 Changes in operating assets and liabilities: Accounts receivable - trade 923,641 981,226 Accrued interest and other receivables 7,105 (32,780) Inventories (340,741) 117,062 Prepaid expenses (14,966) (200,606) Accounts payable (88,849) (288,591) Accrued expenses 1,059,928 378,152 Deferred revenue (21,429) (21,249) ----------- ----------- Total adjustments 2,348,689 1,445,675 ------------ ------------ Net cash provided by operating 4,832,224 3,266,192 ------------ ------------ activities CASH FLOWS FROM INVESTING ACTIVITIES: Capital expenditures for: Property and equipment (1,100,277) (384,335) Intangible assets (250,240) (7,754) Purchases of investments (2,232,923) (500,000) Proceeds from sale of: Investments 3,035,000 1,010,000 Property and equipment 8,250 ------------ ----------- Net cash provided by (used in) investing activities (540,190) 117,911 ----------- ------------ CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock 160,063 105,148 Common stock purchased and retired (1,118,623) (881,081) ----------- ----------- Net cash used in financing activities (958,560) (775,933) ----------- ----------- NET INCREASE IN CASH 3,333,474 2,608,170 CASH AT BEGINNING OF PERIOD 5,064,913 1,579,121 ------------ ------------ CASH AT END OF PERIOD $8,398,387 $4,187,291 ============ ============ SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: Cash paid during the period for $182,245 $143,436 income taxes see notes to consolidated financial statements UTAH MEDICAL PRODUCTS, INC. --------------------------- NOTES TO FINANCIAL STATEMENTS ----------------------------- (unaudited) (1) The unaudited financial statements presented herein have been prepared in accordance with the instructions to form 10-Q and do not include all of the information and note disclosures required by generally accepted accounting principles. These statements should be read in conjunction with the financial statements and notes thereto included in the Utah Medical Products, Inc. ("UTMD", or "the Company") annual report on form 10-K for the year ended December 31, 1995. The accompanying financial statements have not been examined by independent accountants in accordance with generally accepted auditing standards, but in the opinion of management such financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. The results of operations for the three months ended March 31, 1996 may not be indicative of the results that may be expected for the year ending December 31, 1996. (2) Inventories at March 31, 1996 and December 31, 1995 consisted of the following: March 31, December 31, 1996 1995 --------- ------------- Finished goods $998,900 $ 872,419 Work-in-process 893,459 687,746 Raw materials 1,726,365 1,717,817 --------- --------- Total $3,618,724 $3,277,982 ========== ========== (3) In October 1995, the Financial Accounting Standards Board issued SFAS No. 123, "Accounting for Stock-Based Compensation," which defines a fair value based method of accounting for stock based employee compensation plans. Under SFAS No. 123, companies are encouraged, but are not required, to adopt the fair value method for fiscal years beginning after December 15, 1995 for all employee awards granted after the beginning of such year. Companies are permitted to account for such transactions under Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees," (APB No. 25), but must, in future years, disclose in a note to the financial statements proforma net income and earnings per share as if SFAS No. 123 had been applied. The Company has determined it will not adopt the fair value method and therefore will continue to account for stock-based compensation under APB No. 25. ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Results of Operations Because of the relatively short span of time, results for any given three month period in comparison with a previous three month period may not be indicative of comparative results for the year as a whole. a) Overview First quarter (1Q) 1996 revenues were up 2.2% from 1Q 1995, while net income set a new record as it increased 36.4% over the same period. Net income growth out-paced revenue growth due to higher gross and operating margins, as well as much higher non-operating income due to an extraordinary payment received for use of UTMD's pressure monitoring technology. Earnings per share (EPS) benefited modestly from the Company's continuing share repurchase program. EPS in 1Q 1996 grew 36.8% compared with 1Q 1995. b) Revenues UTMD divides revenues into three product-line categories: 1) critical care, which is comprised primarily of components used in invasive blood pressure monitoring, but also includes components for other types of pressure monitoring, as well as disposable respiratory products used in hospitals; 2) obstetrics, which is comprised mainly of devices for monitoring intrauterine pressure during labor and delivery, although to a lesser extent electrodes for fetal heart rate monitoring as well as other labor and delivery supplies, and a new product which unifies and improves clinician safety in the multiple step procedure of clamping, cutting, and drawing blood samples from the umbilical cord immediately following childbirth; and 3) gynecology, which is comprised of an electrosurgery system used in a procedure called LETZ(R), tools used in other minimally invasive surgical procedures including diagnostic laparoscopies, and a device for the conservative treatment of urinary incontinence. In these three areas, UTMD's primary revenue contributors generally: 1) are the accepted standard of care, 2) enjoy a number one or number two market share, and 3) have important product features protected by patents. Critical care product revenues represented 58% of total revenue in 1Q 1996, the same percentage as in 1Q 1995. In the U.S., this is a mature business dominated by two large suppliers, Baxter and Abbott. About a third of the blood pressure monitoring market is for the disposable pressure transducers ("DPT") and accessories which UTMD manufactures and two thirds is for catheters. UTMD participates only in the DPT and accessories niche. Overseas, the market is much more fragmented with DPTs still growing in acceptance. UTMD's Baxter OEM revenue (all of which are included in the critical care category) represented about 66% of critical care revenue (about 38% of total revenues), and grew by 1% in 1Q 1996 over 1Q 1995. Sales of critical care products in 1Q 1996 were $5,790,000, compared with $5,670,000 in 1Q 1995. Sales to Baxter in 1Q 1996 were $3,794,000 compared to $3,743,000 in 1Q 1995. If , as previously announced, Baxter purchases what their forecasts currently indicate, shipments to Baxter in all of 1996 will be about $11 million, down from $15 million in 1995. The obstetrics revenue category declined 1.5% in 1Q 1996 over the same quarter of 1995 and represented 35% of total sales. Sales of obstetrics products in 1Q 1996 were $3,445,000 compared to $3,498,000 in 1Q 1995. Fetal monitoring sales continue to be dominated by INTRANTM, UTMD's sensor-tipped intrauterine pressure catheter. During 1Q 1996, UTMD's largest U.S. distributor, KOL Biomedical (whose purchases are typically over 75% in the obstetrics category) purchased about $800,000 less than expected due to an inventory adjustment. The third category, gynecology products, includes Liberty(R), a system for conservatively treating urinary incontinence, and LuminTM, a unique tool used in laparoscopic procedures to manipulate the uterus, and EpitomeTM, a unique ceramic scalpel, in addition to UTMD's product line of electrosurgery equipment and disposable electrodes. Gynecology revenues increased 23% to $732,000 in 1Q 1996 from $594,000 in 1Q 1995, and represented 7% of total revenues. UTMD's past successes with its gynecology products resulted from providing physician training along with equipment and tools designed for specific procedures. Effective marketing of new products launched in the past year represent significant challenges for UTMD's marketing resources, and will require innovative distribution approaches. First quarter 1996 foreign sales were $2,750,000 compared to $2,562,000 in 1Q 1995. Practically all international sales have been critical care products, for which sales the Company has relied heavily on the efforts of other medical device companies. Critical care products represented 92% of international sales in 1Q 1996 compared to 96% in 1Q 1995. UTMD believes it has substantial sales potential for its products in international markets, and therefore plans to continue to commit its resources to international business expansion, including a new manufacturing facility in Ireland, which should be ready for operation in late 1996. c) Gross Profit Gross margins (profit after subtracting costs of manufacturing products from revenues) in 1Q 1996, were 46.1% compared to 44.8% in 1Q 1995. The improvement in 1Q 1996 is primarily due to manufacturing efficiencies relative to 1Q 1995. Because of anticipated faster sales growth in the obstetrics and gynecology product lines which have higher margins relative to UTMD's other products, and because of declining business with Baxter, the Company foresees continued gross margin improvements. d) Income from Operations Operating profit, or income from operations, is the profit achieved after subtracting operating expenses from gross profit. Operating expenses are subdivided into sales, general and administrative (SG&A) expenses and research and development (R&D) expenses. UTMD further divides SG&A into the two categories of sales and marketing (S&M) expenses and general and administrative (G&A) expenses. As a percentage of sales, operating expenses declined to 18.1% in 1Q 1996 compared to 18.9% in 1Q 1995. Operating expenses for 1Q, in dollars, were down 2% in 1996 from 1995. The portion allocated to R&D declined 14% relative to 1Q 1995. Evidence that R&D efforts over the recent past have been productive is becoming apparent, as UTMD has launched, or is in the process of launching, the following six significant new products: Cordguard(R), Lumin, Liberty, FiltresseTM, Epitome and Deltran IVTM. The FDA is currently reviewing another four submissions for products yet unannounced. In addition, new line extensions include a neonatal ICU torso length respiratory hood, generic loop electrodes for overseas markets and fetal monitoring chart paper. First quarter 1996 selling, general and administrative (SG&A) expenses increased 2% from the amounts spent in 1995, but, as a percentage of sales, declined slightly in 1Q 1996 from 1Q 1995, to 14.5% of sales in 1Q 1996 from 14.6% of sales in 1995. The Company's goal for 1996 is to hold operating expenses to less than 19% of sales. First quarter 1996 R&D expenses were 3.6% of sales compared to 4.3% in 1995. Many R&D expenses are external costs relating to both process and product validations, which costs can vary from period to period. The Company employs its R&D resources not only to internally develop its own new product ideas, but also, through joint development agreements, licensing of technology, acquisitions and other arrangements, to enhance and complete commercialization projects initiated by others. R&D expenses as a percentage of sales will likely continue in 1996 at a rate similar to 1Q 1996. First quarter 1996 income from operations was $2,788,000 compared to $2,531,000 in 1Q 1995. First quarter 1996 operating margins were 28.0% compared to 25.9% for the same quarter in 1995. e) Non-operating Income Non-operating income for UTMD includes principally royalties from licensing UTMD's technology to other companies, interest and capital gains from investing the Company's cash, and gains or losses from the sale of other assets. The major contributor to non-operating income in 1Q 1996 was a one-time extraordinary payment for the use of UTMD's pressure monitoring technology. Non-operating income increased $829,000 to $1,099,000 in 1Q 1996 from $270,000 in 1Q 1995. Royalties from other medical device companies and investment income from cash balances continue to make substantial contributions to non-operating income. Excluding the 1Q one-time payment, royalty income during 1996 should be about the same as in 1995. f) Net Income and EPS After income taxes, 1Q 1996 net income was $2,483,535, compared to $1,820,517 in 1Q 1995. The effective income tax rate in 1Q 1996 was 36.1% compared to 35.0% in 1Q 1995. The higher rate in 1Q 1996 is due to a higher mix of taxable income due to the large one-time non-operating income item versus other tax exempt income, as well as other factors. Shareholder value is improved by increasing EPS. EPS is net income divided by the weighted number of shares of stock outstanding (fully-diluted to include stock options awarded which have exercise prices below the current market value). Future EPS can be increased by investing current net income to increase future net profits through expanded marketable new product offerings and profitable business operations, or by repurchasing stock from the marketplace, thereby reducing the number of outstanding shares. Fully diluted 1Q 1996 EPS were up 36.8% to $.25 compared to $.18 in 1Q 1995. First quarter 1996 ending weighted average number of common shares assuming full dilution (the number used to calculate EPS) were 10,041,513 shares compared to 10,069,086 in 1Q 1995. The dilution calculation added about 255,000 shares to weighted actual shares outstanding in 1Q 1996, compared to about 96,000 for 1Q 1995, due to quarter ending share prices of $16.75 in 1Q 1996 compared to $9.63 in 1Q 1995. Actual outstanding common shares as of March 31, 1996 were 9,727,341. g) Return on Equity Return on shareholders' equity (ROE) is the portion of net income retained by UTMD to internally finance its growth, divided by average accumulated shareholders' equity during the period. The ROE ratio determines how fast the Company can grow without external financing. For example, a 30% ROE would support 30% growth in revenues. Achieving growth in revenues and EPS without diluting shareholder interests maximizes shareholders' value. ROE in 1Q 1996 (annualized) was 33%, and has averaged about 30% during the last 7 years. It is management's objective to maintain ROE in excess of the 25% per annum EPS growth target so that UTMD can afford to grow at a 25% rate without diluting shareholders' interests. External equity financing would only be considered if an exceptional business growth opportunity presents itself that would allow long term increased EPS at the same time that the number of shares are also expanded. h) Cash Flows Cash and investments balances were $15.7 million at the end of 1Q 1996, an increase of $2.5 million from December 31, 1995. The increase was achieved despite continuation of the share repurchase program which used $1,119,000 during the quarter. Cash provided by operating activities, including adjustments for depreciation and other non-cash operating expenses, along with changes in working capital, totaled $4,832,224 in 1Q 1996, up from $3,266,192 in 1Q 1995. Apart from net income, which contributed over half of the 1Q 1996 total, an increase of $1.1 million in income taxes payable (part of accrued expenses) and a decrease of $924 thousand in accounts receivable were responsible for a major portion of the improvement compared to 1Q 1995. As of March 31, 1996, net accounts receivable balances were $5.5 million which equates to 50 days in receivables (based on 1Q sales), compared to end-of-year accounts receivable of $6.5 million which equates to about 55 days in receivables. Inventory balances are $341,000 higher than at the end of 1995, with inventory turns now at 5.9 times based on 1Q cost of sales. Cash of $1.1 million was used for capital expenditures in property and equipment, with an additional $250 thousand used to purchase intangible assets. Capital expenditures during 1Q 1996 were made, primarily, in the new Ireland facility, but also in automation of key assembly operations, and in new product tooling and equipment. Net purchases and sales of investments provided $802 thousand to 1Q 1996 cash. First quarter 1996 financing activities used cash of $959,000 after repurchases of shares are netted against sales of shares from option exercises, compared to $776,000 in the same period of 1995. The Company repurchased its own common stock during 1Q 1996 in the amount of $1,119,000, up from $881,000 used in 1Q 1995. To the end of 1Q 1996, UTMD had spent about $21.9 million in repurchasing 2,525,000 of its common shares since November 1992. In 1Q 1996, the Company received $160,000 from issuing stock (on exercise of employee options), compared to $105,000 in 1Q 1995. The Company did not enter into any long-term debt agreements during the first quarter of 1996. Management believes that current cash balances plus future income from operations will provide the liquidity needed to finance growth plans. In addition to the capital expenditures outlined above, UTMD plans to use cash during the remainder of 1996 for completion of the manufacturing plant in Ireland, for continued share repurchases and for selective infusions of technological, marketing or product manufacturing rights to broaden the Company's product offerings. Other On February 2, 1996, the board of directors approved stock option awards representing a total of 190,000 shares to 50 employees. Of this total, 95,000 were awarded to senior management. An objective of the ongoing share repurchase program is to reduce or eliminate any dilutive effect that may result from awarding employee stock options. A number of the forward-looking factors discussed in this filing are subject to a high degree of uncertainty, particularly in light of the Company's high growth objectives and a rapidly changing healthcare environment. Investors are encouraged to consider all of these factors in that actual results may differ materially from those projected by management. PART II - OTHER INFORMATION ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K a) Exhibits: None b) Reports on Form 8-K: None SIGNATURES Pursuant to the requirements of the Securities Exchanges Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. UTAH MEDICAL PRODUCTS, INC. --------------------------- REGISTRANT Date: By:/S/ May 14, 1996 ------------------------------------- /s/ Kevin L. Cornwell President and CEO Date: By:/S/ May 14, 1996 -------------------------------------- /s/ Kevin L. Cornwell Secretary and CFO EX-27 2
5 THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM BALANCE SHEETS AS OF MARCH 31, 1996 AND STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. 3-MOS DEC-31-1996 MAR-31-1996 8,398,387 7,343,850 5,633,191 (94,406) 3,618,724 25,809,269 15,911,847 (6,355,938) 35,951,297 4,678,604 0 0 0 97,273 30,679,347 35,951,297 9,967,590 9,967,590 5,372,531 1,807,221 (942,769) 0 (155,989) 3,886,596 1,403,061 2,483,535 0 0 0 2,483,535 0.25 0.25
-----END PRIVACY-ENHANCED MESSAGE-----